Ediphor Limited

Ediphor in 30 seconds... #Diagnostics #DigitalHealth #HealthTech #FutureOfHealthcare #HealthcareStartups #HealthcareInvestors #HealthcareInnovation

Ediphor is delighted to announce the appointment of Professor Anthony Goldstone CBE to its Advisory Board. This strategic appointment marks another significant milestone in Ediphor’s plan to deliver low cost, digitally native, lab-quality diagnostic tests that anyone can use anytime, anywhere. Professor Goldstone is a senior haematology specialist with over 35 years’ experience of working in the NHS. He was appointed as a Consultant at University College Hospital (UCH) in 1976 and initiated the first stages of what became the biggest Adult Haematology unit in the UK. Professor Goldstone is a former Medical Director of University College London Hospital, former President of the British Society of Haematology, and former Chair of the European Society for Blood and Marrow Transplantation Lymphoma Group. The founder of the stem cell transplant unit at UCH, Professor Goldstone is a renowned pioneer in haematological stem cell transplantation. Professor Goldstone has published over 360 peer-reviewed papers in haematology and has authored three books. He was awarded a CBE June 2008 for Services to Medicine. Welcome to the team Anthony! #diagnostics #medicaldiagnostics #PointOfCare #digitalhealth #digitaldiagnostics #healthtech

Ediphor is pleased to announce the launch of its Professional Beta Program. Our innovative, high-tech #diagnostic platform is now being used in-the-field in Europe. During the beta program, ETER-MED clinic staff were impressed with the convenience and speed of Ediphor compared to traditional laboratory analysis, redefining the testing experience for healthcare professionals and patients alike. ETER-MED commented, “the Ediphor device is incredible. The speed, ease-of-use, and accuracy of the device will improve efficiency of our operations at a much-reduced cost”. This marks a significant step in our journey to bring accurate, affordable and accessible diagnostics to the forefront of #healthcare. Our beta program is expanding to other markets in the coming weeks in order to gather invaluable feedback from real-world use in advance of full commercial launch. #diagnostics #medicaldiagnostics #PointOfCare #digitalhealth #digitaldiagnostics #healthtech

Ediphor completes its independent clinical trial for its novel Flu test with 99.3% accuracy. Ediphor, a novel Point-Of-Care and personal digital diagnostics company, is pleased to announce the completion of an independent clinical trial for its novel Flu test. Ediphor’s second-generation Flu test exhibited 100% specificity and 98.4% sensitivity in an independent clinical trial of 800 samples (300 positive and 500 negative). The results were compared against lateral flow and PCR flu tests. The clinical trial was conducted by the Medical University of Gdańsk, a highly regarded academic and research institution in Poland, renowned for its extensive experience in medical research, clinical trials and performance evaluations. This milestone result for the Company is further validation of the Ediphor diagnostic platform. The Company is targeting a commercial launch in January 2025.

Ediphor is delighted to announce the appointment of Sir David Sloman to its Advisory Board. This strategic appointment marks a significant milestone in Ediphor’s plan to transform pre-primary care and facilitate remote clinical decision making. Sir David is the former Chief Operating Officer of NHS England in 2023, and prior to that, had 24 years of experience as Chief Executive Officer of several NHS trusts in London. Sir David was awarded a knighthood in 2017 for his services to the NHS and is a Fellow of The Royal Society of Medicine. His career highlights include leading the Royal Free London to foundation status and guiding the NHS in London through the early stages of the COVID-19 pandemic. “I am delighted to join Ediphor’s Advisory Board and contribute to their novel and innovative approach to diagnostics testing At-Home and at Point-of-Care,” commented Sir David. “We urgently need digital solutions like Ediphor to facilitate pre-primary care and improve the efficiency of health care networks globally.” Welcome Sir David!

We are delighted to announce that we have been selected to join London & Partners’ Grow London Global programme, supported by the Mayor of London. We’ll be joining the 12 month programme to gain access to support in unlocking our global growth ambitions and expanding internationally. For more information, visit grow.london/global

Ediphor is preparing to launch its second-generation digital diagnostics platform in Q4 2024. The Ediphor platform is portable, digitally connected and scalable, delivering rapid (<3 min diagnosis), ultra-low-cost (<£5/assay) molecular diagnostic testing with class-leading sensitivity (2-20 copies/sample) and specificity (>98%) for At-Home and Point-of-Care settings. For enquiries, please visit www.ediphor.com #AtHomeDiagnostics  #hometesting #HealthcareRevolution #medicaldevices #digitalhealth #Innovation #nhsdigital #POCDiagnostics